Indoco Remedies Limited (IN:INDOCO)
:INDOCO
Want to see IN:INDOCO full AI Analyst Report?
INDOCO Stock Chart & Stats
₹228.35
-₹0.55(-0.16%)
At close: 4:00 PM EST
₹228.35
-₹0.55(-0.16%)
Day’s Range― - ―
52-Week Range₹163.70 - ₹348.10
Previous CloseN/A
Volume47.33K
Average Volume (3M)38.33K
Market Cap
₹19.50B
Enterprise Value₹30.08B
Total Cash (Recent Filing)₹231.50M
Total Debt (Recent Filing)₹9.99B
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)-12.73
Shares Outstanding92,303,604
10 Day Avg. Volume7,145
30 Day Avg. Volume38,334
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)1.55
Price to Sales (P/S)0.79
P/FCF Ratio-12.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.08
Revenue Forecast (FY)₹20.55B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelIndoco’s mix of branded generics, generic formulations, APIs and CDMO services creates multiple durable revenue channels. This diversification reduces reliance on any single market or product, supports cross‑selling, and smooths demand swings across domestic and international markets over months.
Reasonable Gross Margins And Revenue GrowthA sustained gross margin near 41% together with ~9–11% revenue growth indicates enduring product economics and market traction. If operating costs are controlled, these fundamentals allow room to restore operating leverage and convert top‑line growth into durable profit recovery over several quarters.
Scale Manufacturing CapabilityOwning multiple manufacturing facilities supports cost efficiencies, higher throughput and the ability to service both domestic branded markets and export/API contracts. Scale aids regulatory approvals, contract credibility for CDMO customers, and long‑term capacity to meet growing regulated market demand.
Bears Say
Two Years Of Net LossesConsecutive annual losses signal enduring profitability issues, eroding retained earnings and return metrics. Persistent net losses constrain reinvestment, limit buffer against shocks, and make recovery dependent on sustained margin improvement or structural cost reductions over multiple quarters.
Rising LeverageMaterially higher leverage reduces financial flexibility and raises refinancing and interest coverage risk, especially with weak profits. Increased debt magnifies downside if cash generation remains poor, making balance‑sheet repair a multi‑quarter priority to restore resilience.
Weak Free Cash FlowDeeply negative free cash flow after capex signals cash burn and an inability of operations to fund investment and obligations. This creates structural funding needs, heightens dilution or borrowing risk, and limits capacity to support growth or absorb regulatory/product delays over the medium term.
Indoco Remedies Limited News
INDOCO FAQ
What was Indoco Remedies Limited’s price range in the past 12 months?
Indoco Remedies Limited lowest stock price was ₹163.70 and its highest was ₹348.10 in the past 12 months.
What is Indoco Remedies Limited’s market cap?
Indoco Remedies Limited’s market cap is ₹19.50B.
When is Indoco Remedies Limited’s upcoming earnings report date?
Indoco Remedies Limited’s upcoming earnings report date is Jul 28, 2026 which is in 68 days.
How were Indoco Remedies Limited’s earnings last quarter?
Indoco Remedies Limited released its earnings results on May 07, 2026. The company reported -₹2.45 earnings per share for the quarter, beating the consensus estimate of -₹3.55 by ₹1.1.
Is Indoco Remedies Limited overvalued?
According to Wall Street analysts Indoco Remedies Limited’s price is currently Overvalued.
Does Indoco Remedies Limited pay dividends?
Indoco Remedies Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.08%. See more information on Indoco Remedies Limited dividends here
What is Indoco Remedies Limited’s EPS estimate?
Indoco Remedies Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Indoco Remedies Limited have?
Indoco Remedies Limited has 92,303,604 shares outstanding.
What happened to Indoco Remedies Limited’s price movement after its last earnings report?
Indoco Remedies Limited reported an EPS of -₹2.45 in its last earnings report, beating expectations of -₹3.55. Following the earnings report the stock price went up 10.222%.
Which hedge fund is a major shareholder of Indoco Remedies Limited?
Currently, no hedge funds are holding shares in IN:INDOCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Indoco Remedies Limited
Indoco Remedies Limited manufactures and sells formulations and active pharmaceutical ingredients in India and internationally. The company offers respiratory products, such as Karvol Plus, Febrex Plus, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform Toothpaste, Sensoform Gum Paint, Rexidin M, Rexidin SRS, RR Sensoform Dental, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastrointestinal products, such as Carmicide, Cyclopam, Cyclomeff, and Nosic; pain/analgesics products that include Lignox and T-lac; and ophthal/otologicals products, such as Renolen, Homide, Dexoren S, Zincoren, Otorex, Mofloren-D, and Mofloren LP. It also provides vitamins/minerals/nutrients that include Methycal, Cital UTI, SM Fibro, Cal Aid, SM Fibro, MCBM DHA, and Apispur; urology products, such as Carmicide and Cital; Cloben G and Scabex for dermatology; ATM for anti-infectives; Hemsyl for blood related; MCBM 69 and D Chiro for gynecological; and Spear for anti-haemorrhoidal. In addition, the company provides analytical services, such as impurity profile, particle size analysis, heavy metal analysis, polymorphism and compatibility studies, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, it offers services that include architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. The company serves general practitioners, pediatricians, consultant physicians, dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.
Technical Analysis
Alembic Pharmaceuticals Limited
―
Hikal Limited
―
Morepen Laboratories Limited
―
Solara Active Pharma Sciences Ltd.
―
Unichem Laboratories Limited
―